Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.
McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero J, Seymour M, Saltz LB, Giantonio BJ, Arnold D, Rothenberg ML, Koopman M, Schmoll HJ, Pitot HC, Hoff PM, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, Yoshino T, Chibaudel B, deGramont A, Shi Q, Lichtman SM. McCleary NJ, et al. Among authors: sobrero af. JNCI Cancer Spectr. 2022 Mar 2;6(2):pkac014. doi: 10.1093/jncics/pkac014. JNCI Cancer Spectr. 2022. PMID: 35603849 Free PMC article.
Does biomodulation of 5-fluorouracil improve results?
Sobrero AF, Herrmann R, Rischin D, Zalcberg J. Sobrero AF, et al. Eur J Cancer. 1999 Feb;35(2):186-94. doi: 10.1016/s0959-8049(98)00362-1. Eur J Cancer. 1999. PMID: 10448257 Review. No abstract available.
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Van Cutsem E, et al. Br J Cancer. 2004 Mar 22;90(6):1190-7. doi: 10.1038/sj.bjc.6601676. Br J Cancer. 2004. PMID: 15026800 Free PMC article. Clinical Trial.
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Twelves CJ, Butts CA, Cassidy J, Conroy T, Braud Fd, Diaz-Rubio E, Tabernero JM, Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ. Twelves CJ, et al. Among authors: sobrero af. Clin Colorectal Cancer. 2005 Jul;5(2):101-7. doi: 10.3816/ccc.2005.n.021. Clin Colorectal Cancer. 2005. PMID: 16098250
Current issues in adjuvant treatment of stage II colon cancer.
André T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, Misset JL, Boni C, de Gramont A. André T, et al. Ann Surg Oncol. 2006 Jun;13(6):887-98. doi: 10.1245/ASO.2006.07.003. Epub 2006 Apr 14. Ann Surg Oncol. 2006. PMID: 16614880 Review.
First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A. Pessino A, et al. Ann Oncol. 2008 Apr;19(4):711-6. doi: 10.1093/annonc/mdm516. Epub 2007 Dec 10. Ann Oncol. 2008. PMID: 18073221 Free article. Clinical Trial.
230 results